Skip to content
Axcess News – Lifestyle
Author:
Opus Genetics, Inc.
Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting
March 6, 2026
Opus Genetics Announces FDA Acceptance of Supplemental New Drug Application for Phentolamine Ophthalmic Solution 0.75% for the Treatment of Presbyopia
March 5, 2026
←
Previous Page
1
2
3